Melatonin attenuates phenytoin sodium-induced DNA damage

Drug and Chemical Toxicology

Volumn 37, Issue 2, 2014, Pages 233-239

  Erenberk, Ufuk ^a   Dundaroz, Rusen ^a   Gok, Ozlem ^a   Uysal, Omer ^b   Agus, Sami ^a   Yuksel, Adnan ^c   Yilmaz, Bayram ^d   Kilic, Ulkan ^a  

^a Department of Pediatrics ^*  (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d YEDITEPE UNIVERSITY   (Turkey)

Author keywords

Antioxidants; DNA damage; Melatonin; Oxidative stress; Phenytoin sodium; Rat

Indexed keywords

ALCOHOL; MELATONIN; PHENYTOIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; LYMPHOCYTE; MALE; NONHUMAN; RAT;

ANIMALS; ANTICONVULSANTS; COMET ASSAY; DNA DAMAGE; ETHANOL; FREE RADICAL SCAVENGERS; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTES; MALE; MELATONIN; OXIDATIVE STRESS; PHENYTOIN; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 84896695392     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480545.2013.838777     Document Type: Article

References (50)

1. Ames BN, Shigenaga M, Gold LS. (1993). DNA lesions, inducible DNA repair and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 101:35-44.
2. Bittigau P, Sifringer M, Ikonomidou C. (2003). Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci 993:103-114.
3. Bhuller Y, Wells PG. (2006). A developmental role for ataxia-telangiectasia mutated in protecting the embryo from spontaneous and phenytoin-enhanced embryopathies in culture. Toxicol Sci 93: 156-163.
4. Bhuller Y, Jeng W, Wells PG. (2006). Variable in vivo embryoprotective role for ataxia-telangiectasia-mutated against constitutive and phenytoin- enhanced oxidative stress in atm knockout mice. Toxicol Sci 93: 146-155.
5. Cheung RT, Tipoe GL, Tam S, et al. (2006). Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res 41:337-343.
6. Collins A, Dusinska M, Franklin M, et al. (1997). Comet assay in human biomonitoring studies: reliability, validation, and applications. Environ Mol Mutagen 30:139-146.
7. Dziegiel P, Suder E, Surowiak P, et al. (2002). Role of exogenous melatonin in reducing the nephrotoxic effect of daunorubicin and doxorubicin in the rat. J Pineal Res 33:95-100.
8. Galano A, Tan DX, Reiter RJ. (2011). Melatonin as a naturally against oxidative stress: a physicochemical examination. J Pineal Res 51: 1-16.
9. Gitto E, Karbownik M, Reiter RJ, et al. (2001a). Effects of melatonin treatment in septic newborns. Pediatr Res 50:756-760.
10. Gitto E, Tan DX, Reiter RJ, et al. (2001b). Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 53:1393-1401.
11. Hamed SA, Abdullah MM, El-Melegy N. (2004). Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J Pharmacol Sci 96:465-473.
12. Hara M, Yoshida M, Nishijima H, et al. (2001). Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 30:129-138.
13. Hardeland R, Backhaus C, Fadavi A. (2007). Reactions of the NO redox forms NO, NO and HNO (protonated NO) with the melatonin metabolite N1-Acetyl-5-methoxykynuramine. J Pineal Res 43: 382-388.
14. Hardeland R, Tan DX, Reiter RJ. (2009). Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 47:109-126.
15. Katz I, Kim J, Gale K, Kondratyev A. (2007). Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. J Pharmacol Exp Ther 322: 494-500.
16. Kaul A, Kalla NR, Goyle S. (2001). An altered proliferative response due to the anticonvulsant phenytoin (PHT) in epileptic patients. Teratog Carcinog Mutagen 21:151-164.
17. Kilic E, Kilic U, Reiter RJ, et al. (2004). Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 37:247-251.
18. Kilic U, Kilic E, Reiter RJ, et al. (2005). Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res 38:67-71.
19. Kilic U, Yilmaz B, Ugur M, et al. (2012). Evidence that membranebound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J Pineal Res 52:228-235.
20. Kilic U, Kilic E, Tuzcu Z, et al. (2013). Melatonin suppresses cisplatininduced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab (Lond) 10:7 (1-8).
21. Kim PM, Winn LM, Parman T, et al. (1997). UDP-glucuronosy ltransferase mediated protection against in vitro DNA oxidation and icronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5- phenylhydandoin. J Pharmacol Exp Ther 280:200-209.
22. Kopjar N, Miocic S, Ramic S, et al. (2006). Assessment of the radioprotective effects of amifostine and melatonin on human lymphocytes irradiated with gamma-rays in vitro. Arh Hig Rada Toksikol 57:155-163.
23. Lialiaris T, Lyratzopoulos E, Papachristou F, et al. (2008). Supplementation of melatonin protects human lympho cytes in vitro from the genotoxic activity of melphalan. Mutagenesis 23:347-354.
24. Lovell DP, Omori T. (2008). Statistical issues in the use of the comet assay. Mutagenesis 23:171-182.
25. Lowenstein DH. (1998). Seizures and epilepsy. In: Fauci AS, Martin JB, Braunwald E, et al. eds. Harrisons principles of internal medicine, 14th ed. New York: McGraw-Hill, 2315-2316.
26. Mahle C, Dasgupta A. (1997). Decreased total antioxidant capacity and elevated lipid hydroperoxide concentrations in sera of epileptic patients receiving phenytoin. Life Sci 61:437-443.
27. Manda K, Ueno M, Anzai K. (2007). AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 42:386-393.
28. Mayo JC, Tan DX, Sainz RM, et al. (2003). Oxidative damage to catalase induced by peroxyl radicals: functional protection by melatonin and other antioxidants. Free Radic Res 37:543-553.
29. Murray JC, Hill RM, Hegemier S, et al. (1996). Lymphoblastic lymphoma following prenatal exposure to phenytoin. J Pediatr Hematol Oncol 18:241-243.
30. Nava M, Romero F, Quiroz Y, et al. (2000). Melatonin attenuates acute renal failure and oxidative stress induced by mercury chloride in rats. Am J Physiol Renal Physiol 279:910-918.
31. Ortiz GG, Benitez-King GA, Rosales-Corral SA, et al. (2008). Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders. Curr Neuropharmacol 6: 203-214.
32. Pei Z, Pang SF, Cheung RT. (2002). Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res 32:168-172.
33. Reiter RJ, Tan DX, Osuna C, et al. (2000). Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 7:444-458.
34. Reiter RJ, Tan DX, Sainz RM, et al. (2002). Melatonin reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54: 1299-1321.
35. Reiter RJ, Tan DX, Manchester LC, et al. (2003). Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol 527:539-548.
36. Reiter RJ, Tan DX, Leon J, et al. (2005). When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med 230:104-117.
37. Reiter RJ, Paredes SD, Manchester LC, et al. (2009). Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 44:175-200.
38. Sandal S, Yilmaz B, Carpenter DO. (2008). Genotoxic effects of PCB 52 and PCB 77 on cultured human peripheral lymphocytes. Mutat Res 654:88-92.
39. Sener G, Sehirli AO, Altunbas HZ, et al. (2002). Melatonin protects against gentamicin-induced nephrotoxicity in rats. J Pineal Res 32: 231-236.
40. Singh G, Driever PH, Sander JW. (2005). Cancer risk in people with epilepsy: the role of anti-epileptic drugs. Brain 128:7-17.
41. Sun FY, Lin X, Mao LZ, et al. (2002). Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J Pineal Res 33:48-56.
42. Tan DX, Chen LD, Poeggeler B, et al. (1993). Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J 1:57-60.
43. Tan DX, Manchester LC, Terron MP, et al. (2007). One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res 42:28-42.
44. Urata Y, Honma S, Goto S, et al. (1999). Melatonin induces gammaglutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 27:838-847.
45. Ustundag A, Duydu Y. (2007). The influence of melatonin and N-Acetylcysteine in delta-Aminolevulinic acid and lead induced genotoxicity in lymphocytes in vitro. Biol Trace Elem Res 117: 53-64.
46. Wells PG, Winn LM. (1997). The role of biotransformation in developmental toxicity. In: Sipes IG, McQueen CA, Gandolfi AJ, eds. Comprehensive toxicology. Tarrytown (NY): Pergamon Elsevier Science, 479-497.
47. Wells PG, McCallum GP, Lam KCH, et al. (2010). Oxidative DNA damage and repair in teratogenesis and neurodevelopmental deficits. Birth Defects Res C Embryo Today 90:103-109.
48. Winn LM, Wells PG. (1995). Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol Pharmacol 48:112-120.
49. Winn LM, Wells PG. (1999). Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic Biol Med 26:266-274.
50. Winn LM, Kim PM, Nickoloff JA. (2003). Oxidative stress-induced homologous recombination as a novel mechanism for phenytoininitiated toxicity. J Pharmacol Exp Ther 306:523-527.